Amorfix Life Sciences Ltd. (Amorfix) is a Canada-based product development company focused on therapeutic antibodies and diagnostics for the diagnosis and treatment of misfolded protein diseases, including amyotrophic lateral sclerosis (ALS), cancer and Alzheimer's disease (AD). Its technology includes the Epitope Protection technology, ProMIS and AMFIA. Amorfix's technology targets misfolded superoxide dismutase 1 (SOD1) through a passive infusion of manufactured monoclonal antibodies and an active immunization approach to elicit the production of similar antibodies by the patient's own immune system. The Company is engaged in the development of a blood test that measures misfolded SOD1 in blood, for the diagnosis of ALS. Amorfix has developed both a preclinical test for detection and measurement of aggregated Abeta, a recognized biomarker for AD, in animal models and a test for the detection of aggregated Abeta in human clinical samples.